NewsMarkets

Business

Hims & Hers Launches Unapproved Compounded Peptide Treatments

The telehealth company adds five FDA-unapproved compounds to its menu following regulatory shifts that have expanded the market for such treatments.

3 publishers · 4 articles · first seen 18 Nov 2026 · updated 2d ago

Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made

First reported by CNBC, 5h 04m ahead of the next publisher · who breaks stories first

This story has stopped developing; this page is its permanent record. More from that day

The odds

How the odds moved · BPC-157
0%50%100%75%18 Nov, 16:19 UTCnowSTAT: STAT+: Peptide market poised to explode with new Hims and Noom launches · 19 Nov, 16:59 UTCQuartz: Hims & Hers bringt fünf zusammengesetzte Peptidbehandlungen auf den Markt, die nicht von der FDA zugelassen sind. · 18 Nov, 19:10 UTCQuartz: Hims & Hers is launching five compounded peptide treatments not approved by the FDA · 18 Nov, 19:07 UTC

Each tick is a source publishing on this story · 1 more published before price tracking began

Price data
TimeChance of yes
now75%
18 Nov, 16:19 UTC75%

The story so far

3 publishers have covered this in 4 articles since 18 Nov 2026. CNBC published first, on 18 November at 14:02 UTC; Quartz followed 5h 04m later. The most recent article, from STAT, appeared on 19 November at 16:59 UTC.

Outlets reporting it: CNBC (major outlet), Quartz, STAT.

One prediction market prices this story:

  • BPC-157 — the market puts it at 75%, closing 1 Oct 2027. The outcome is Yes if the FDA publishes a proposed rule adding BPC-157 or its acetate form to the 503A Bulks List before October 1, 2027. Otherwise, the outcome is No. Readers often mistake the launch of compounded treatments for an official FDA action.

Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy CNBC ·
  2. STAT+: Peptide market poised to explode with new Hims and Noom launches STAT
  3. Hims & Hers bringt fünf zusammengesetzte Peptidbehandlungen auf den Markt, die nicht von der FDA zugelassen sind. Quartz
  4. Hims & Hers is launching five compounded peptide treatments not approved by the FDA Quartz

Related prediction markets

Linked by software because they are about the same subject. Most ask a different question from the one this story reports, so read each market's own question. How often the link is right

  • Kalshi BPC-157 · Which peptides will the FDA propose adding to the 503A Bulks List? 75% $0 24hends 1 Oct 2027

    Does the market have this right?

    Wrong market?

Have your say

Your call. How does this end?

Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls

Alert me when the odds move

Email: we send a link to confirm first, and you can unsubscribe in one click. Browser notifications need no email and are turned off on the Following page. At most one alert every six hours either way. Privacy

In this story

  • Hims & Hers
  • Noom
  • FDA
  • HHS
Embed this story

Paste this into any web page to show the live odds, with a link back here.